enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
13F holders, Q1 2024
Institutional positions in enGene Therapeutics Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −8 vs. Q4 2023
- Shares held
- 5.50M
- −1.83M (−25.0%) vs. Q4 2023
- Total value
- $28.6M
- +$22.4M (+359.7%) vs. Q4 2023
- New holders
- 0
- 2 more added
- Sold out
- 8
- 10 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.54M |
| Q1 2026 | 11 | $12.9M |
| Q4 2025 | 14 | $13.9M |
| Q3 2025 | 17 | $3.29M |
| Q2 2025 | 15 | $3.70M |
| Q1 2025 | 14 | $2.91M |
| Q4 2024 | 15 | $4.02M |
| Q3 2024 | 14 | $9.20M |
| Q2 2024 | 16 | $6.54M |
| Q1 2024 | 16 | $28.6M |
| Q4 2023 | 25 | $6.26M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 2,878,148 | $15.0M | 2.12% | −1,000,000−25.8% | Reduced |
| BVF Inc | 945,402 | $4.92M | 0.14% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 511,177 | $2.66M | 0.53% | +36,100+7.6% | Added |
| Omega Fund Management, LLC | 360,903 | $1.88M | 1.21% | −114,174−24.0% | Reduced |
| Saba Capital Management, L.P. | 193,963 | $1.01M | 0.02% | −36,507−15.8% | Reduced |
| Calamos Advisors LLC | 150,000 | $780.0K | 0.00% | −100,000−40.0% | Reduced |
| D. E. Shaw & Co., Inc. | 104,622 | $544.0K | 0.00% | −100−0.1% | Reduced |
| Polar Asset Management Partners Inc. | 97,391 | $516.5K | 0.01% | −83,332−46.1% | Reduced |
| Atalaya Capital Management LP | 66,666 | $346.7K | 0.41% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 65,000 | $338.0K | 0.01% | −51,666−44.3% | Reduced |
| Cowen and Company, LLC | 34,998 | $182.0K | 0.01% | −103,714−74.8% | Reduced |
| Whitebox Advisors LLC | 33,333 | $173.3K | 0.01% | 00.0% | Unchanged |
| State of Wisconsin Investment Board | 23,570 | $122.6K | 0.00% | 00.0% | Unchanged |
| CSS LLC | 20,000 | $104.0K | 0.01% | −7,000−25.9% | Reduced |
| Wolverine Asset Management LLC | 12,690 | $66.0K | 0.00% | +7,057+125.3% | Added |
| Clear Street LLC | 5,000 | $26.0K | 0.00% | −23,410−82.4% | Reduced |
| Highbridge Capital Management LLC | 0 | $0 | 0.00% | – | Sold out |
| CNH Partners LLC | 0 | $0 | 0.00% | −127,339−100.0% | Sold out |
| Periscope Capital Inc. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Shaolin Capital Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Kim, LLC | 0 | $0 | 0.00% | −33,333−100.0% | Sold out |
| Aristeia Capital LLC | 0 | $0 | 0.00% | −24,045−100.0% | Sold out |
| Sculptor Capital LP | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −11,200−100.0% | Sold out |
| Exos TFP Holdings LLC | – | – | – | – | Not filed |